XORTX Therapeutics Inc.
XRTXRating Trend
Earnings History
Next report: Nov 12, 2026| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 17, 2026 | $-1.05 | — | — | — |
| May 19, 2026 | $-0.58 | — | — | — |
| Feb 26, 2026 | $-0.45 | $-0.84 | — | — |
| Nov 15, 2025 | $-0.65 | $-0.32 | — | — |
| Aug 14, 2025 | $-0.95 | $-1.25 | — | — |
| May 19, 2025 | $-0.95 | $-1.35 | — | — |
| May 15, 2025 | $-0.20 | $-1.45 | — | — |
| Nov 14, 2024 | $-1.00 | $-1.92 | — | — |
News
● Clinical Trial Application planned for filing with Health Canada, extending the Company's international regulatory strategy for gout program XRx-026 ● CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide an outline of its anticipated Clinical Trial Application (“CTA”) submiss…
Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company's regulatory path toward NDA filing for gout program XRx-026 Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company's regulatory path toward NDA filing for gout program XRx-026
● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ●
CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) announces that, following completion of its previously announced voluntary delisting from the TSX Venture Exchange, XORTX has re-engaged IR Agency LLC pursuant to a consulting agreement providing for investor relations and marketing services on substantially the same terms previously disclosed by the Company in its news releases dated May 19, 2026 and August 28, 2026.
CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “IR Agreement”). The IR Agreement had a 90-day term…